Company intelligence / Profile preview

Altheia Science

Milan, Lombardia, Italy

Ownership: Private
Development stage: Other

Overview

Altheia Science has active collaborations and robust manufacturing partnerships—in particular with Anemocyte for plasmid DNA and viral vector supply—accelerating development of cell and gene therapies for autoimmune diseases; no published clinical results yet but the company is described as pioneering and advancing toward clinical trials.

Therapeutic areas: ImmunologyOncology
Modalities: Cell therapyGene therapy
Industry: Biotech

Drug pipeline

2 assets

PD-L1-expressing autologous hematopoietic stem and progenitor cells

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Anemocyte (manufacturing, plasmid DNA, cell banks, viral vector supply)

Beyond the preview

Go deeper on Altheia Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altheia Science.

Explore the full profile